1. Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug.
- Author
-
Bi J, Khan A, Tang J, Armando AM, Wu S, Zhang W, Gimple RC, Reed A, Jing H, Koga T, Wong IT, Gu Y, Miki S, Yang H, Prager B, Curtis EJ, Wainwright DA, Furnari FB, Rich JN, Cloughesy TF, Kornblum HI, Quehenberger O, Rzhetsky A, Cravatt BF, and Mischel PS
- Subjects
- Animals, Antineoplastic Agents metabolism, Antineoplastic Combined Chemotherapy Protocols pharmacology, Brain Neoplasms metabolism, Brain Neoplasms pathology, Cell Line, Tumor, Electronic Health Records, ErbB Receptors metabolism, Female, Fluoxetine metabolism, Glioblastoma metabolism, Glioblastoma pathology, Humans, Mice, Nude, Permeability, Retrospective Studies, Sphingomyelin Phosphodiesterase antagonists & inhibitors, Sphingomyelin Phosphodiesterase metabolism, Sphingomyelins metabolism, Temozolomide pharmacology, Tumor Burden drug effects, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, Mice, Antineoplastic Agents pharmacology, Blood-Brain Barrier metabolism, Brain Neoplasms drug therapy, Drug Repositioning, Energy Metabolism drug effects, Fluoxetine pharmacology, Glioblastoma drug therapy, Signal Transduction drug effects
- Abstract
The highly lethal brain cancer glioblastoma (GBM) poses a daunting challenge because the blood-brain barrier renders potentially druggable amplified or mutated oncoproteins relatively inaccessible. Here, we identify sphingomyelin phosphodiesterase 1 (SMPD1), an enzyme that regulates the conversion of sphingomyelin to ceramide, as an actionable drug target in GBM. We show that the highly brain-penetrant antidepressant fluoxetine potently inhibits SMPD1 activity, killing GBMs, through inhibition of epidermal growth factor receptor (EGFR) signaling and via activation of lysosomal stress. Combining fluoxetine with temozolomide, a standard of care for GBM, causes massive increases in GBM cell death and complete tumor regression in mice. Incorporation of real-world evidence from electronic medical records from insurance databases reveals significantly increased survival in GBM patients treated with fluoxetine, which was not seen in patients treated with other selective serotonin reuptake inhibitor (SSRI) antidepressants. These results nominate the repurposing of fluoxetine as a potentially safe and promising therapy for patients with GBM and suggest prospective randomized clinical trials., Competing Interests: Declaration of interests P.S.M. is co-founder of Boundless Bio, Inc. He has equity in the company, chairs the scientific advisory board, and serves as a consultant, for which he is compensated. P.S.M. is also consultant for Autobahn Therapeutics, Inc. and Sage Therapeutics. These consulting arrangements started after completion of this paper., (Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF